product name GW441756
Description: GW441756 is a potent, selective inhibitor of TrkA with IC50 of 2 nM, with very little activity to c-Raf1 and CDK2. The activity of TrkA kinase can affect its downstream signaling and involves in many biological processes including proliferation, differentiation and apoptosis. In human muscle sarcoma cancer cell line HTB114, treatment of GW441756 dose-dependently suppresses neoplastic proliferation and induces apoptosis.
References: Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7; Exp Mol Med. 2008 Jun 30; 40(3): 276–285; Mol Cells. 2008 Jul 31;26(1):12-7.
275.3
Formula
C17H13N3O
CAS No.
504433-23-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 25 mg/mL (90.8 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: GW441756 can specifically block TrkA-induced cell death in a dose-dependent manner. GW441756 can block TrkA-mediated γH2AX production and apoptosis in TrkA-overexpressing cells. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7. |
